NCT05203237
VK2735 obesity Phase 2
Phase Phase 2
Status Active, not recruiting
Indication Obesity
Enrollment 176
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT05203237
- Phase
- Phase 2
- Status
- Active, not recruiting
- Indication
- Obesity
- Primary completion
- 12/1/2025
- Enrollment (planned/actual)
- 176
- Sponsor
- Viking Therapeutics
- Peptide
- VK2735
Peptide under study
VK2735
Dual GLP-1 / GIP agonist · Phase 2